Number of the records: 1
In-vitro antiplatelet effect of melatonin in healthy individuals and patients with type 2 diabetes mellitus
- 1.
SYSNO ASEP 0572274 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title In-vitro antiplatelet effect of melatonin in healthy individuals and patients with type 2 diabetes mellitus Author(s) Böhm, A. (SK)
Lauko, V. (SK)
Dostálová, K. (SK)
Balanová, I. (SK)
Varga, I. (SK)
Bezák, B. (SK)
Jajcay, Nikola (UIVT-O) RID, ORCID, SAI
Moravčík, R. (SK)
Lazurová, L. (SK)
Slezák, P. (SK)
Mojto, V. (SK)
Kollárová, M. (SK)
Petríková, K. (SK)
Daňová, K. (SK)
Zeman, M. (SK)Source Title Journal of Endocrinological Investigation - ISSN 0391-4097
Roč. 46, č. 12 (2023), s. 2493-2500Number of pages 8 s. Language eng - English Country US - United States Keywords Melatonin ; Acute myocardial infarction ; Circadian variation ; Diabetes mellitus ; Platelet aggregation OECD category Cardiac and Cardiovascular systems Method of publishing Open access Institutional support UIVT-O - RVO:67985807 UT WOS 000982997300002 EID SCOPUS 85158112126 DOI 10.1007/s40618-023-02102-7 Annotation PURPOSE: The incidence of acute myocardial infarctions (AMI) shows circadian variation typically peaking during morning hours with a decline at night. However, this variation does not occur in patients with diabetes mellitus (DM). The night’s decline of AMI may be partially explained by melatonin-related platelet inhibition. Whether this effect is absent in diabetic patients is unknown. The aim was to study the effect of melatonin on in-vitro platelet aggregation in healthy individuals and patients with type 2 DM. METHODS: Platelet aggregation was measured in blood samples from healthy individuals (n = 15) and type 2 DM patients (n = 15) using multiple electrode aggregometry. Adenosine diphosphate (ADP), arachidonic acid (ASPI) and thrombin (TRAP) were used as agonists. Aggregability for each subject was tested after adding melatonin in two concentrations. RESULTS: In healthy individuals, melatonin inhibited platelet aggregation in both higher (10–5 M) and lower concentrations (10–9 M) induced by ADP, ASPI, and TRAP (p < 0.001, p = 0.002, p = 0.029, respectively). In DM patients, melatonin did not affect platelet aggregation in both concentrations induced by ADP, ASPI, and TRAP. Melatonin decreased platelet aggregation induced by ADP, ASPI, and TRAP significantly more in healthy individuals compared to patients with DM. (p = 0.005, p = 0.045 and p = 0.048, respectively). CONCLUSION: Platelet aggregation was inhibited by melatonin in healthy individuals. In-vitro antiplatelet effect of melatonin in type 2 DM patients is significantly attenuated. Workplace Institute of Computer Science Contact Tereza Šírová, sirova@cs.cas.cz, Tel.: 266 053 800 Year of Publishing 2024 Electronic address https://dx.doi.org/10.1007/s40618-023-02102-7
Number of the records: 1